Paul Geyer

Paul Geyer discloses dealings in Eupraxia Pharmaceuticals Inc. to SEDI. We count 8 filings; the first trade dates from 8 March 2021 and the latest from 18 March 2026.

Sales make up the whole of the open-market record (1 sale, €103k). Outside the open market, there are 1 share grant and 1 option exercise. In 2026 alone, the filings show no purchases and 1 sale.

The record was last updated on 18 March 2026 with a transaction in Eupraxia Pharmaceuticals Inc. The median gap between a trade and its publication by SEDI is 4 days. Until a filing is published, the market cannot know about the trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.